Drug costs

It’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation.

Analysis from Prime shows that improvements in persistency, adherence is key in RA treatments.

Promising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.

Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.

A report from the Alliance of Community Health Plans can help get a better sense of how well drugs help patients compared to other treatment options.

Find out where each presidential candidate stands on key issues related to pharmaceutical costs.

A new database helps payers understand which genetic tests are available, which genes they test for, and which tests would be appropriate to use to inform patient management.

There are promising developments in the pipeline for patients with treatment-resistant depression.

Managed Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results.

Expert: Expectations are high that biosimilars can control overall biologic cost growth.

Systematic review provides comprehensive first look at TNF-alpha biosimilar treatments.

Obesity and associated comorbidities strain the healthcare system, so why has R&D for new weight loss medications been lackluster?

Obesity affects almost 38% of U.S. adults, according to the CDC’s National Health and Nutrition Examination Survey. Here’s how plans and providers can create positive change.

Timely and broad use of Entresto could prevent or postpone more than 28,000 US deaths per year among HFrEF patients, according to research in JAMA Cardiology.

Expanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.

Despite their proliferation, at-risk pharma contracts are still little more than value-based window dressing. Here are four critical components of contracts that can actually move the value meter in the right direction.

New analysis finds proposed Medicare payment changes for physician-administered drugs would reduce reimbursement for those that cost more than $480 per day in 2016. Seven of the 10 drugs that constitute the largest reduction in reimbursement are used to treat cancer.

IMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference.

AMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching

At AMCP, four stakeholders representing the specialty pharmacy perspective, manufacturer perspective, payer perspective, and PBM perspective shared their thoughts on the future of specialty pharmacy.

A new report from IMS Institute for Healthcare Informatics finds that biosimilar acceptance will grow and drive change in the healthcare system.

Here are 10 solutions that come together to provide a multifaceted approach to medication adherence.

A number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?

PCSK9 inhibitor benefits patients with statin intolerance

The sheer volume of diabetes patients has made it a big driver of medication spending. Here are some important formulary considerations.